Rapamycin (Sirolimus)
An approved mTOR-inhibiting immunosuppressant explored off-label for longevity using intermittent weekly dosing. Interest centers on its effects on cellular aging pathways.
- Half-life
- 2.5 d
- Out of system
- ~13 days
- Route
- Oral
- Level
- Intermediate
Levels carry over between doses — every 2–3 days is typical. After the last dose, roughly 97% has cleared in ~13 days (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Rapamycin (Sirolimus) is used for
- Inhibits mTOR, a pathway central to cellular aging in many studies
- Intermittent dosing aims to capture benefits while limiting side effects
- Decades of clinical safety data exist from its approved uses
How it's typically used
Off-label longevity protocols describe roughly 6 mg once weekly, framed as reported practice and not a recommendation.
What to watch for
- Immunosuppressive, which can raise infection risk
- Can raise blood lipids and glucose and cause mouth sores
- Longevity dosing is off-label and not proven for that purpose
- A prescription medication; the anti-aging use is investigational and not approved
About Longevity
- What they are
- Compounds studied for cellular ageing — mitochondrial function, senescent-cell clearance, telomere and autophagy pathways.
- How they're run
- Mixed routes: some injected in short annual or biannual courses, others taken orally every day.
- What to watch
- Endpoints here are measured in decades, so nobody has human outcome data. Bloodwork and function markers are the only feedback you will get in a realistic timeframe.
Full guide
Rapamycin (Sirolimus): A Tracking Guide for an mTOR Inhibitor
An evidence-aware look at rapamycin, the headline off-label longevity drug, what the human data actually shows, and what to monitor on intermittent dosing.
Other longevity
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.